Trial Profile
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Midostaurin (Primary) ; Cytarabine; Daunorubicin; Idarubicin
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Expanded access
- Acronyms Radius-X
- Sponsors Novartis Pharmaceuticals
- 17 Jan 2019 Status changed from recruiting to completed.
- 04 Dec 2018 Results assessing safety data for midostaurin during induction and consolidation and safety data during the maintenance phase presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 12 Dec 2017 Results (data cut off: 28 Feb, 2017) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology